Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 28

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 28
---
 assurance that Cara will be able to regain compliance within the extension period, by consummation of the Merger or otherwise, and maintain its listing on The Nasdaq Capital Market. If Cara does not regain compliance within the extension period, or if Cara fails to satisfy another Nasdaq requirement for continued listing, the Staff could provide notice that Cara’s securities will become subject to delisting. In such event, Nasdaq rules would permit Cara to appeal the delisting determination to a Nasdaq Hearings Panel. The hearing request would ordinarily stay any suspension or delisting action pending the conclusion of the hearing process and the expiration of any additional extension period granted by the panel following the hearing, but there can be no assurance that any such appeal would be successful. The continued listing of the shares of Cara common stock is a condition to the closing of the Merger unless waived by the Tvardi Board in its sole discretion. If Cara is unable to timely regain compliance with the minimum stockholders’ equity requirement, it is unknown whether the Tvardi Board will grant a waiver to this condition until such a time (if ever) that such a determination by the Tvardi Board becomes necessary. For more information, refer to the section titled “ Risk Factors Related to the Merger — Cara or Tvardi may waive one or more of the conditions to the Merger without recirculation of this proxy statement/prospectus or resoliciting stockholder approval ” beginning on page 31 of this proxy statement/prospectus and “ Risk Factors — The Merger may not be completed on the terms or timeline currently contemplated, or at all .” beginning on page 27of this proxy statement/prospectus.

<div align='center'>11</div>

TABLE OF CONTENTS

#### Tvardi Therapeutics, Inc.
3 Sugar Creek Center Blvd., Suite 525 
 Sugar Land, Texas 77478 
 (713) 489-8654

Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Tvardi is leveraging its deep understanding of the transcription factor, STAT3, to develop a pipeline of oral small molecules with a differentiated mechanism of action to directly inhibit STAT3, a highly validated, yet historically undruggable target. Tvardi’s lead product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and